Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation: Clinical Trials & FDA Approval Profile

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (Global / Institutional) sponsors 26 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 4 active protocols (1 recruiting now), 5 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)110 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)26
Active Pipeline (Recruiting Now)4 (1)
Completed vs Stopped Early5 / 0 (0.0%)
Median Closed Actual Enrollment110 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Explore interactive annual charts and M&A subsidiary rollups in the Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Interactive Dossier, benchmark peers in Infectious Disease and Vaccines, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI